Economic burden of diabetes-related hypoglycemia on patients, payors, and employers
- PMID: 33836965
- DOI: 10.1016/j.jdiacomp.2021.107916
Economic burden of diabetes-related hypoglycemia on patients, payors, and employers
Abstract
The economic and psychological consequences of diabetes-related hypoglycemic events are multifold and shared across various parties, including patients and their family or caregivers, payors, and employers. Hypoglycemic events contribute to increased morbidity, mortality, and a substantial portion of diabetes economic burden. Both severe and non-severe hypoglycemic episodes contribute to economic and psychological burden, and can have short-term consequences, such as emergency services, hospitalization, clinic visits, and increased use of diabetes supplies. Severe hypoglycemic events also generate additional follow-up costs, and are likely to occur again. Left untreated, hypoglycemia can have long-term consequences including, death, cardiovascular events, and cognitive issues. Costs vary geographically based on the treatment protocols which focus on outpatient treatment versus increased in-patient hospitalization. Certain types of medications are also associated with increased hypoglycemia, which requires closer monitoring of the patient, such as with basal insulin initiation. Some individuals with diabetes may be more vulnerable to hypoglycemia, such as the elderly, postoperative bariatric patients, and adolescent females. Measures to mitigate hypoglycemia are essential to ease the economic burden of these events. Medication management, optimal glucose control, lifestyle modifications and frequent glucose monitoring are some interventions which may help prevent hypoglycemia.
Keywords: Economic burden; Healthcare utilization; Hypoglycemia; Non-severe hypoglycemia; Severe hypoglycemia; Type 1 diabetes; Type 2 diabetes.
Copyright © 2021. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest VF: reports grants (to Tulane) from, BI. Honoraria for Consulting and Lectures: Takeda, Novo Nordisk, Sanofi- Aventis, Asahi, Abbott Diabetes Care. Stock Options: BRAVO4Health, Mellitus Health. LS: no disclosures to report. BC: reports other from Becton Dickenson, outside the submitted work.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
